Publications
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination or in close sequence…
2021 OHE Annual Report to the Charity Commission
1 December 2022
OHE obtained its charitable status in 2016, an essential achievement towards OHE’s development as a health economics research organisation. The report of 2021 demonstrates some of…
Supporting the Era of Green Pharmaceuticals in the UK
1 November 2022
This report sets out the high-priority activities that the NHS, UK government and industry should undertake to tackle the challenge of reducing the NHS’s carbon footprint.
Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques
1 July 2022
Fertility treatments, collectively termed Assisted Reproductive Techniques (ART), are now widely available for routine clinical use. However, there is a lack of cost-effectiveness evidence for fertility treatments. This, in part, reflects challenges associated with estimating the health-related quality of life (HRQoL) impacts of infertility and subfertility.
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth…
Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
1 June 2022
Gene therapies represent a new era of medicine, offering the potential for truly transformational health gains, and further benefits for society and health systems.
When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
1 March 2022
Generic preference-based measures are often used for capturing patients’ health-related quality of life (QOL) to assess quality-adjusted life years (QALYs) in health technology assessment (HTA). Whilst…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS…